Physician profile

Tyanne T Van

Psychiatric/Mental Health (Nurse Practitioner) · Chandler, AZ

NPI 1952808800

$594.46

in general payments reported to CMS, 2019-2025

6 companies · none reported in 2025

See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$382.05

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Gilead Sciences, INC. $291.04 2021-2024
Astrazeneca Pharmaceuticals LP $181.09 2023-2024 Breztri, Farxiga
Abbvie INC. $46.82 2022
Kowa Pharmaceuticals America, INC. $33.68 2023 Livalo
Abbott Laboratories $22.64 2022
Esperion Therapeutics, INC. $19.19 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Tyanne T Van

$594.46

in general payments reported 2019-2025

Years
2021-2024
Top company
Gilead Sciences, INC.

https://glasscript.com/doctor/11082262/tyanne-t-van

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.